DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 207 filers reported holding DENALI THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.17 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $239,308 | -22.0% | 11,600 | +11.5% | 0.00% | -33.3% |
| Q2 2023 | $306,904 | -2.8% | 10,400 | -24.1% | 0.00% | 0.0% |
| Q1 2023 | $315,648 | -10.6% | 13,700 | +7.9% | 0.00% | -25.0% |
| Q4 2022 | $353,187 | -11.5% | 12,700 | -2.3% | 0.00% | -20.0% |
| Q3 2022 | $398,970 | -15.1% | 13,000 | -11.0% | 0.01% | +25.0% |
| Q1 2022 | $470,000 | -59.0% | 14,600 | -43.2% | 0.00% | -50.0% |
| Q4 2021 | $1,146,000 | -20.6% | 25,700 | -10.1% | 0.01% | -46.7% |
| Q3 2021 | $1,443,000 | -17.1% | 28,600 | +28.8% | 0.02% | -11.8% |
| Q2 2021 | $1,741,000 | +48.0% | 22,200 | +7.8% | 0.02% | +54.5% |
| Q1 2021 | $1,176,000 | +142.0% | 20,600 | +255.2% | 0.01% | +120.0% |
| Q4 2020 | $486,000 | -2.4% | 5,800 | -58.3% | 0.01% | -16.7% |
| Q3 2020 | $498,000 | – | 13,900 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 19,462,500 | $339,037,000 | 35.95% |
| Euclidean Capital LLC | 323,749 | $27,117,000 | 5.74% |
| Flagship Pioneering Inc. | 2,730,263 | $228,687,000 | 4.16% |
| Casdin Capital, LLC | 1,310,000 | $109,726,000 | 3.25% |
| A.R.T. Advisors, LLC | 6,173 | $517,000 | 2.39% |
| MARK ASSET MANAGEMENT LP | 172,040 | $14,410,000 | 1.73% |
| Temasek Holdings (Private) Ltd | 4,410,457 | $369,420,000 | 1.59% |
| Integral Health Asset Management, LLC | 57,500 | $4,816,000 | 1.43% |
| GILDER GAGNON HOWE & CO LLC | 3,219,843 | $269,694,000 | 1.34% |
| IRONWOOD INVESTMENT MANAGEMENT LLC | 19,365 | $1,622,000 | 0.95% |